SK pharmteco et Prozomix annoncent une collaboration stratégique visant à renforcer leurs capacités en matière de biocatalyse pour la fabrication de médicaments à l’échelle mondiale

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• As drug molecules become increasingly complex, the use of enzymes offers a greener, more selective, and more cost-effective alternative to traditional chemical synthesis

  60% confidence

• Prozomix's ability to quickly deliver large quantities of optimized enzymes coupled with SK pharmteco's manufacturing excellence ensures clients can transition from discovery phase to commercial-scale production with unmatched speed and reliability

  60% confidence

• SK pharmteco's mission is to forge strong relationships with industry leaders based on trust, quality, and a shared commitment to reliably deliver medicines meeting more demanding standards

  60% confidence

• The partnership with SK pharmteco will fully exploit the potential of Prozomix's enzyme range in the most demanding pharmaceutical applications

  60% confidence

• Prozomix has earned a global reputation for reducing risks associated with early bioprocess development through its highly diverse enzyme sets and rapid scale-up capabilities

  60% confidence

• Integration of Prozomix's enzymatic diversity into SK pharmteco's global R&D and manufacturing process complements their current technology platforms and helps offer clients more innovative and sustainable solutions

  60% confidence

Cited in these Via News reports

• Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →